Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer

Ursula A. Matulonis, MD
Published: Monday, Mar 13, 2017



Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

The NOVA trial started a number of years ago, which examines the oral PARP inhibitor, niraparib, explains Matulonis. Patients partaking in the study had to have platinum-sensitive recurrent ovarian cancer and show responsiveness to the platinum-based agent.

This trial was a 2:1 randomization, which enrolled several hundred patients. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.
 


Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

The NOVA trial started a number of years ago, which examines the oral PARP inhibitor, niraparib, explains Matulonis. Patients partaking in the study had to have platinum-sensitive recurrent ovarian cancer and show responsiveness to the platinum-based agent.

This trial was a 2:1 randomization, which enrolled several hundred patients. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x